Business Context and Reporting Period
The supplied filing is NanoAntibiotics, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2013—not a BioVie Inc. filing. The company was incorporated in April 2013 and describes itself as a development-stage biotechnology company pursuing broad-spectrum antibiotics. It had no products for sale or revenue. The filing covers the three and six months ended December 31, 2013 and, in some statements, the period since inception.
Financial Results and Position
| Metric | Three months ended Dec. 31, 2013 | Six months ended Dec. 31, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $19,150 | $30,010 |
| Selling, general and administrative expense | $28,132 | $70,855 |
| Net loss | $47,126 | $100,619 |
| Basic and diluted loss per share | $0.00 | $0.00 |
- At December 31, 2013, cash and total assets were $406,827; current liabilities were $16,750, consisting of accrued expenses. The filing reports no debt.
- Six-month operating cash use was $98,869. No investing cash flows or financing proceeds were reported for the six-month period; inception-to-date financing from stock issuance was $508,206.
- Stockholders’ equity was $390,077. The company had 87,060,000 common shares outstanding at January 23, 2014.
- No meaningful prior-year comparable results are provided; the company began operations in 2013. The filing reports no gross margin because it had no sales.
Changes, Outlook, and Risks
- Cash decreased from $505,696 at June 30, 2013 to $406,827 at December 31, 2013. The company states that available funds are insufficient for planned activities over the next 12 months and estimates it needs approximately $330,000 in additional net financing.
- For the next 12 months, management estimated $500,000 for research and development, $100,000 for corporate overhead, $75,000 for capital costs, and $100,000 for staffing. The company said existing cash was expected to fund operations only until approximately March 31, 2014.
- Development priorities include MRSA candidates and drug-resistant tuberculosis candidates. Management described the compounds as having been studied only in cell-based, in-vitro assays; animal efficacy and toxicity studies had not been conducted. FDA approval and commercial success are uncertain, and substantial additional development and funding are needed.
- Management warned that inability to raise funds could require reductions or delays in development, licensing to third parties, a strategic transaction, or cessation of operations. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
- The company reported that it acquired rights, formulations, studies, and data related to efflux-pump antibiotics from Kard Scientific and its president in October 2013; the assets were recorded at zero historical cost. It also disclosed a five-year office lease executed January 1, 2014, with aggregate payments of $21,420.
- Management concluded that disclosure controls and procedures were not effective as of December 31, 2013. No material change in internal control over financial reporting during the quarter was reported. No material legal proceedings were disclosed.
Key Facts to Verify
- Confirm the issuer and filing identity: the request names BioVie Inc., while the provided 10-Q identifies NanoAntibiotics, Inc.
- Resolve an R&D expense inconsistency: the income statement reports $19,150 for the quarter, while a footnote states $28,750 for the same three-month period.
- Review financing availability and whether the estimated additional $330,000 was raised, given the stated short cash runway and going-concern uncertainty.
- Assess the status, results, and costs of planned preclinical studies, and whether the candidates advance beyond in-vitro testing.
- Clarify the company’s reporting-period and comparative-period presentation, since the filing is for the quarter ended December 31, 2013 and does not provide prior-year comparisons.